IL158744A0 - Methods for treating delirium using glucocorticoid receptor-specific antagonists - Google Patents

Methods for treating delirium using glucocorticoid receptor-specific antagonists

Info

Publication number
IL158744A0
IL158744A0 IL15874402A IL15874402A IL158744A0 IL 158744 A0 IL158744 A0 IL 158744A0 IL 15874402 A IL15874402 A IL 15874402A IL 15874402 A IL15874402 A IL 15874402A IL 158744 A0 IL158744 A0 IL 158744A0
Authority
IL
Israel
Prior art keywords
glucocorticoid receptor
methods
treating delirium
specific antagonists
receptor antagonist
Prior art date
Application number
IL15874402A
Other languages
English (en)
Original Assignee
Corcept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc
Publication of IL158744A0 publication Critical patent/IL158744A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
IL15874402A 2001-05-04 2002-05-06 Methods for treating delirium using glucocorticoid receptor-specific antagonists IL158744A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28861901P 2001-05-04 2001-05-04
US13780002A 2002-05-01 2002-05-01
PCT/US2002/014318 WO2002096433A1 (en) 2001-05-04 2002-05-06 Methods for treating delirium using glucocorticoid receptor-specific antagonists

Publications (1)

Publication Number Publication Date
IL158744A0 true IL158744A0 (en) 2004-05-12

Family

ID=26835589

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15874402A IL158744A0 (en) 2001-05-04 2002-05-06 Methods for treating delirium using glucocorticoid receptor-specific antagonists
IL158744A IL158744A (en) 2001-05-04 2003-11-04 Method for the treatment of insanity using glucocorticoid-specific receptor antagonists

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL158744A IL158744A (en) 2001-05-04 2003-11-04 Method for the treatment of insanity using glucocorticoid-specific receptor antagonists

Country Status (11)

Country Link
EP (1) EP1390037B1 (enExample)
JP (2) JP2005512949A (enExample)
CN (1) CN1527713A (enExample)
AT (1) ATE492281T1 (enExample)
AU (1) AU2002303652B2 (enExample)
CA (1) CA2446506C (enExample)
DE (1) DE60238671D1 (enExample)
IL (2) IL158744A0 (enExample)
NO (1) NO334736B1 (enExample)
NZ (1) NZ529456A (enExample)
WO (1) WO2002096433A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2463446C (en) * 2001-10-26 2010-02-23 Akzo Nobel N.V. Use of (11.beta., 17.beta.)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one in the treatment of major depressive disorder
CN103930027B (zh) * 2011-10-07 2016-03-02 皇家飞利浦有限公司 用于监测患者并检测该患者的谵妄的监测系统
CN116168840B (zh) * 2023-04-23 2023-12-22 北京大学人民医院 一种预测术后谵妄发生风险的方法、设备及系统

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3464012B2 (ja) * 1993-04-05 2003-11-05 旭化成株式会社 精神症候治療剤
IL110309A0 (en) * 1993-07-15 1994-10-21 Univ Kentucky Res Found A method of protecting against neuron loss
CN1528315A (zh) * 1997-10-06 2004-09-15 ������˹̹�������ѧ�й�ίԱ�� 治疗糖皮质素功能失调相关性精神病的方法
CN1130200C (zh) * 1998-05-15 2003-12-10 利兰·斯坦福青年大学托管委员会 用于治疗痴呆的糖皮质激素受体拮抗剂
CN1556709A (zh) * 2001-03-23 2004-12-22 �Ƹ��� 使用糖皮质激素受体特效拮抗剂治疗压力症的方法

Also Published As

Publication number Publication date
JP2005512949A (ja) 2005-05-12
AU2002303652B2 (en) 2006-08-31
CA2446506C (en) 2012-04-10
NO20034916D0 (no) 2003-11-04
NZ529456A (en) 2005-10-28
EP1390037A4 (en) 2005-03-30
IL158744A (en) 2011-11-30
NO20034916L (no) 2004-01-05
CA2446506A1 (en) 2002-12-05
DE60238671D1 (de) 2011-02-03
EP1390037B1 (en) 2010-12-22
WO2002096433A9 (en) 2003-02-06
NO334736B1 (no) 2014-05-19
JP2009102346A (ja) 2009-05-14
HK1059036A1 (en) 2004-06-18
ATE492281T1 (de) 2011-01-15
EP1390037A1 (en) 2004-02-25
WO2002096433A1 (en) 2002-12-05
CN1527713A (zh) 2004-09-08

Similar Documents

Publication Publication Date Title
CY1108562T1 (el) Μεθοδοι για την προληψη προσληψης βαρους η οποια προκαλειται απο αντιψυχωτικες θεραπειες
WO2002076390A3 (en) Methods for treating stress disorders using glucocorticoid receptor-specific antagonists
IL139672A (en) Glucocorticoid receptor antagonists for the tretment of dementia
CA2302586A1 (en) Methods for treating psychosis associated with glucocorticoid related dysfunction
WO2004058717A8 (en) Isoquinolinone derivatives and their use as therapeutic agents
WO2005028480A3 (en) 5-aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds
HK1047050A1 (zh) 治疗轻度智力机能缺陷的方法
IL164793A0 (en) Methods for increasing the therapeutic response toelectroconvulsive therapy ("ect")
IL160649A0 (en) Methods for inhibiting cognitive deterioration in adults with down syndrome
AP2003002920A0 (en) 5-substituted-2-arylpyridines as CRF1 modulators
MXPA06000662A (es) Antagonistas del receptor muscarinico de acetilcolina.
WO2004069202A3 (en) Antiglucocorticoids for the treatment of postpartum psychosis
TW200519109A (en) Muscarinic acetylcholine receptor antagonists
TW200519108A (en) Muscarinic acetylcholine receptor antagonists
IL158744A0 (en) Methods for treating delirium using glucocorticoid receptor-specific antagonists
AU2003231019A8 (en) Pharmaceutical compositions containing alpha3beta4 nicotinic receptor antagonists and methods of their use
WO2002020526A3 (en) Cyclic and acyclic amidines and pharmaceutical compositions containing them for use as progesterone receptor binding agents
EP1726307A3 (en) Methods for treating psychosis associated with glucocorticoid related dysfunction